India to Honduras: Acetaminophen Export Trade Route

To import Acetaminophen formulations into Honduras, foreign manufacturers must appoint a Local Authorized Representative (LAR) or local distributor to act as the registration holder. The registration process mandates the submission of a comprehensive dossier adhering to ARSA's guidelines for Medicamento Registro Sanitario. This dossier should include:

• Administrative Documents: Apostilled Free Sale Certificate, WHO-GMP Certificate, and Contract Manufacturing Agreement.

• Technical Documents: Quantitative and Qualitative Formula, Finished Product Specifications, Method of Analysis, Monograph, Method Validations, Artworks (Primary & Secondary), Package Insert (in Spanish), Stability Protocol and Data (aligned with climatic Zone IVb: 30°C ± 2 / RH 75% ± 5), API Certificate of Analysis (COA), and Finished Product COA.

All labeling, including cartons and inserts, must be accurately translated into Spanish. The typical validity of product registration is five years, after which renewal is required. Post-approval changes, such as artwork, formulation, or manufacturing site modifications, necessitate notification or variation filing. ARSA may also request product samples for laboratory testing during the registration process.

Indian exporters of Acetaminophen formulations must comply with WHO-GMP standards to supply the Honduran market. Facilities should possess valid GMP certifications and be prepared for potential inspections by ARSA to verify compliance. As of March 2026, specific details regarding ARSA's inspections or regulatory actions against Indian pharmaceutical companies are not publicly disclosed. However, adherence to international GMP standards and maintaining up-to-date certifications are crucial for market access.

In 2025, Honduras established three specialized institutions under ARSA: the National Centre for Technovigilance, the National Centre for Pharmacovigilance, and the National Centre for Foodborne Diseases. These centers aim to enhance the control and safety of medical devices, pharmaceuticals, and food products. This development underscores Honduras's commitment to strengthening its regulatory framework, potentially impacting the approval timelines and post-market surveillance for imported pharmaceutical products.

Indian exporters should stay informed about these regulatory changes and ensure compliance with any new guidelines or requirements introduced by ARSA to facilitate the smooth importation of Acetaminophen formulations into Honduras.

In 2025, the analgesics market in Honduras is projected to generate revenue of approximately $36.15 million, with acetaminophen formulations constituting a significant portion due to their widespread use in pain and fever management. The market is expected to experience an annual growth rate of 7.46% from 2025 to 2030, driven by factors such as increasing healthcare awareness, a growing aging population, and the prevalence of chronic pain conditions. While specific data on domestic production of acetaminophen formulations in Honduras is limited, the country relies on imports to meet its demand, with India being a notable supplier.

Honduras maintains a 0% MFN import duty rate for pharmaceutical products classified under HS code 30049069, which includes acetaminophen formulations. This exemption aligns with the country's commitment to ensuring affordable access to essential medicines. Additionally, there are no specific Free Trade Agreements (FTAs) between India and Honduras that further affect pharmaceutical tariffs. The absence of import duties and anti-dumping measures on these products underscores Honduras's dedication to facilitating the importation of critical healthcare products.

India is a key exporter of acetaminophen formulations to Honduras, with a trade value of $1.2 million, accounting for 0.5% of India's total acetaminophen formulation exports. The top Indian exporters include SAGA LIFESCIENCES LIMITED ($0.3M), MEDICO REMEDIES LIMITED ($0.2M), and CAPLIN POINT LABORATORIES LIMITED ($0.1M). Major buyers in Honduras are ANPHAR SA de CV ($0.2M), LABORATORIOS FARSIMAN, S.A. ($0.1M), and NUEVOS ETICOS NEOETHICALS, S.A. ($0.1M). While specific data on other countries supplying acetaminophen formulations to Honduras is not readily available, India's established pharmaceutical industry and competitive pricing position it as a significant player in the Honduran market. The cost-effectiveness of Indian pharmaceutical products, coupled with the 0% import duty, enhances their appeal in Honduras.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global generics trade. (zipdo.co) The country's pharmaceutical manufacturing sector boasts an annual capacity exceeding 70 billion dosage units, encompassing a wide range of finished dosage forms, including tablets, capsules, and syrups. This extensive production capability is supported by over 1,000 pharmaceutical companies with active research and development facilities, ensuring continuous innovation and quality improvement. (zipdo.co)

India's cost-effective production is a significant advantage, with manufacturing costs approximately 30% to 35% lower than those in the United States and Europe. This cost efficiency is primarily due to lower labor costs, stringent cost-control measures, and the accelerated adoption of digital technologies. Furthermore, India houses 752 FDA-approved manufacturing facilities and 2,050 WHO-GMP certified plants, the highest number outside the United States, ensuring adherence to international quality standards.

These factors collectively position India as a preferred source for acetaminophen formulations globally, offering a combination of high-quality production, cost efficiency, and substantial manufacturing capacity.

In the third quarter of 2025, the average price per metric ton of paracetamol (acetaminophen) was $2,911 in India, $3,415 in China, and $3,496 in Germany. This indicates that India's pricing is more competitive compared to China and the European Union.

India's pharmaceutical industry is renowned for its adherence to international quality standards, with 752 FDA-approved and 2,050 WHO-GMP certified manufacturing facilities. This extensive regulatory compliance ensures that Indian acetaminophen formulations meet global quality benchmarks.

In contrast, while China and the EU also maintain high-quality standards, India's combination of cost-effectiveness and stringent regulatory compliance offers a compelling advantage. Additionally, India's pharmaceutical exports have demonstrated a strong track record of supply reliability, with a 40% increase in on-time-in-full delivery rates between 2014 and 2023.

For buyers in Honduras, sourcing acetaminophen formulations from India presents a strategic opportunity to procure high-quality products at competitive prices, supported by a reliable supply chain.

India's pharmaceutical industry has significantly enhanced its supply reliability and manufacturing capacity in recent years. Between 2014 and 2023, there was a 40% increase in on-time-in-full delivery rates, surpassing the global average of 1%. This improvement is attributed to substantial investments in infrastructure, automation, and quality control systems.

The country operates 752 FDA-approved and 2,050 WHO-GMP certified manufacturing facilities, ensuring adherence to international quality standards. These facilities are equipped with advanced packaging and cold chain capabilities, essential for maintaining the integrity of pharmaceutical products during transit.

There have been no significant supply disruptions reported in recent years, indicating a stable and reliable supply chain. Indian manufacturers have also demonstrated a strong regulatory compliance track record, with a 50% reduction in FDA Official Action Indicated (OAI) outcomes over the last decade.

Leading Indian pharmaceutical companies continue to expand their manufacturing capacities to meet growing global demand. For instance, Granules India Limited has Paracetamol production capacities exceeding 25,000 metric tons annually across three WHO-GMP facilities.

These factors collectively ensure a robust and reliable supply of acetaminophen formulations from India to international markets, including Honduras.

For buyers in Honduras seeking to source acetaminophen formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply chain.

• Minimum Order Quantities (MOQs): Indian suppliers typically require MOQs to optimize production and logistics. It's essential to negotiate MOQs that align with your demand forecasts and storage capabilities.

• Payment Terms: Common payment terms in India-Honduras pharmaceutical trade include Letters of Credit (LC) and advance payments. Establish clear payment agreements to maintain smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities, verification of regulatory certifications (such as FDA and WHO-GMP approvals), and assessment of quality control systems.

• Regulatory Compliance: Ensure that the selected suppliers comply with both Indian and Honduran pharmaceutical regulations to facilitate seamless importation and distribution.

By implementing these strategies, buyers can establish a reliable and cost-effective supply chain for acetaminophen formulations from India.

By meticulously following these guidelines, Honduras companies can establish reliable partnerships with Indian suppliers, ensuring the consistent quality and safety of Acetaminophen formulations imported into the country.